<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427232</url>
  </required_header>
  <id_info>
    <org_study_id>EK 242/2002</org_study_id>
    <nct_id>NCT00427232</nct_id>
  </id_info>
  <brief_title>Endothelin-Receptor Blockade in Coronary Heart Disease</brief_title>
  <official_title>Selective and Non-Selective Endothelin-Receptor Blockade in Coronary Artey Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Endothelin is a hormon that causes acute and chronic narrowing of heart vessels. The purpose&#xD;
      of this study is to assess whether suppression of this activity by using two types of&#xD;
      receptor antagonists can reduce this effect and thus improve blood supply of the heart&#xD;
      muscle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelin (ET) is the most potent vasoconstrictor known and plays a major role in the&#xD;
      development of coronary artery disease as well as in acute vasoconstriction. This effect is&#xD;
      mainly mediated by the vascular ET-A receptor, whereas the ET-B receptor mediates&#xD;
      vasodilation and cleavage of ET. Currently, there are both selective ET-A antagonists and&#xD;
      non-selective ET-A and ET-B antagonists under investigation. The aim of the study is to test&#xD;
      the effect of ET-receptor blockade on the vasoreagibility of epicardial and intramyocardial&#xD;
      coronary arteries in patients undergoing cardiac catheterization. We randomly use the&#xD;
      selective ET-A receptor BQ-123 (Group A) and the combination of BQ-123 and the ET-B receptor&#xD;
      antagonist BQ-788 (Group B). The tested infusion will be applied selectively into the&#xD;
      assessed coronary artery by a special infusion catheter. To evaluate the morphometric changes&#xD;
      we use quantitative coronary angiography to measure the diameter of the coronary artery&#xD;
      before and after intracoronary infusion of the tested substances. Furthermore we will use&#xD;
      Pressure Wire to measure the hemodynamic conditions before and after infusion, thus&#xD;
      evaluating the epicardial and the intramyocardial blood perfusion.&#xD;
&#xD;
      Comparison: Coronary artery diameter as measured by quantitative angiography (minimal lumen&#xD;
      diameter) and parameters indicative of epicardial and intramyocardial blood flow as&#xD;
      determined by Pressure Wire (fractional flow reserver, coronary flow reserve, intramyocardial&#xD;
      resistance) before and after ET-antagonist infusion will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>minimal lumen diameter measured directly after infusion of the ET-antagonist(s)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>fractional flow reserve, coronary flow reserve, intramyocardial resistance measured directly after infusion of the ET-antagonist(s)</measure>
  </secondary_outcome>
  <enrollment>26</enrollment>
  <condition>Coronary Vessels</condition>
  <condition>Endothelins</condition>
  <condition>Vascular Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ-123 and BQ-788</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  coronary artey disease&#xD;
&#xD;
          -  stable angina pectoris&#xD;
&#xD;
          -  male and post-menopausal female patients&#xD;
&#xD;
          -  age above 19 years&#xD;
&#xD;
          -  able and willing to conform to the requirements of the study&#xD;
&#xD;
          -  provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe focal coronary stenosis&#xD;
&#xD;
          -  visually calcified stenosis&#xD;
&#xD;
          -  aorto-ostial lesion location and unprotected left main stenosis&#xD;
&#xD;
          -  pre-menopausal female patients&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  unstable angina pectoris and/or acute Q-wave myocardial infarctaion within the past 72&#xD;
             hours&#xD;
&#xD;
          -  current vasoactive medication&#xD;
&#xD;
          -  previous percutaneous transluminal revascularization at the site of the target lesion&#xD;
&#xD;
          -  lesion which has extremely angulated segments &gt;90%&#xD;
&#xD;
          -  vessel with escessive tortuosity of the proximal segment&#xD;
&#xD;
          -  severe hypotension&#xD;
&#xD;
          -  severely reduced left ventricular function&#xD;
&#xD;
          -  severe carotid stenosis&#xD;
&#xD;
          -  patients with pace maker&#xD;
&#xD;
          -  patients with elevated liver enzymes&#xD;
&#xD;
          -  patients simultaneously participating in another device or drug study&#xD;
&#xD;
          -  inability of unwillingness to comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Neunteufl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Internal Medicine II, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Internal Medicine II, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2007</study_first_posted>
  <last_update_submitted>January 25, 2007</last_update_submitted>
  <last_update_submitted_qc>January 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2007</last_update_posted>
  <keyword>coronary heart disease</keyword>
  <keyword>endothelins</keyword>
  <keyword>coronary angiography</keyword>
  <keyword>blood flow velocity</keyword>
  <keyword>fractional flow reserve, myocardial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BQ 788</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

